Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 6.

Okoniewski, M J; Lesniewska, A; Szabelska, A; Zyprych-Walczak, J; Ryan, M; Wachtel, M; Morzy, T; Schäfer, B; Schlapbach, R (2012). Preferred analysis methods for single genomic regions in RNA sequencing revealed by processing the shape of coverage. Nucleic Acids Research, 40(9):e63.

Wachtel, M; Schäfer, B W (2010). Targets for cancer therapy in childhood sarcomas. Cancer Treatment Reviews, 36(4):318-327.

Hecker, R M; Amstutz, R A; Wachtel, M; Walter, D; Niggli, F K; Schäfer, B W (2010). p21 Downregulation is an important component of PAX3/FKHR oncogenicity and its reactivation by HDAC inhibitors enhances combination treatment. Oncogene, 29(27):3942-3952.

Oesch, S; Walter, D; Wachtel, M; Prêtre, Kathya; Salazar, M; Guzmán, M; Velasco, G; Schäfer, B W (2009). Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma. Molecular Cancer Therapeutics, 8(7):1838-1845.

Grass, B; Wachtel, M; Behnke, S; Leuschner, I; Niggli, F K; Schäfer, B W (2009). Immunohistochemical detection of EGFR, fibrillin-2, P-cadherin and AP2beta as biomarkers for rhabdomyosarcoma diagnostics. Histopathology, 54(7):873-879.

Amstutz, R; Wachtel, M; Troxler, H; Kleinert, P; Ebauer, M; Haneke, T; Oehler-Jänne, C; Fabbro, D; Niggli, F K; Schäfer, B W (2008). Phosphorylation regulates transcriptional activity of PAX3/FKHR and reveals novel therapeutic possibilities. Cancer Research, 68(10):3767-3776.

This list was generated on Thu Feb 21 19:35:54 2019 CET.